Agiomix FZ LLC receives ISO 27001 accreditation

Agiomix announced that its laboratory operation has been awarded the ISO 27001 for information security management systems (ISMS), Mr. Khaled Elsayed, group VP for Technology & Innovation commented on the announcement; “We believe that this achievement reflects our commitment to our customers and partners confidentiality, security of information and the overall level of compliance with international quality control standards, we understand that data security is a major concern for our clients and this accreditation should serve as a sign for them, to show how serious and committed we are towards this matter at Agiomix”

About Agiomix Labs

Agiomix Labs is a group of specialty diagnostics laboratories headquartered in Dubai, the group offers routine and specialty clinical laboratory services serving molecular and genomics applications in the areas, of infectious diseases, oncology, reproductive health, and general wellness. The group has labs spread across the Middle East, Africa, and Asia and its stated mission are to help make precision medicine accessible to emerging and growing markets.

Link to Press Release: https://bit.ly/35JiRve

April 5th, 2022|

Don’t Give Breast Cancer A Chance To Win

October, the breast cancer awareness month, gives us an opportunity to stand alongside breast cancer patients, supporting and guiding them through their difficult journey.

An internal event was held on October 12 called “Don’t Give Breast Cancer a Chance To Win” in which employees shared their thoughts, personal stories, and testimonials emphasizing how to give hope and determination to moving forward.

To watch the video from the event, please visit our LinkedIn https://bit.ly/2Z2qfOv or YouTube https://bit.ly/3nc5TdX channels.

breast cancer

October 31st, 2021|

Agiomix Reveals New Products During Medlab 2021

Agiomix, the first ISO 15189 and CAP accredited clinical next-generation laboratory in the region, took part in Medlab Middle East 2021, the region’s leading medical laboratory exhibition. During the event, which took place at the Dubai World Trade Center between 21st to 24th June 2021, Agiomix unveiled its latest products; EndoPredict and NIPTunegx.

Medlab Middle East is an established event focused on lead products and services in relation to medical laboratories around the region, bringing together medical laboratory, healthcare and trade professionals. With so many participants in the medical field in one place, Medlab 2021 proved to be the ideal setting to make connections and gain valuable feedback. Visitors and attendees expressed their interest in the diverse line-up of preexisting and new products, ranging from gene sequencing with ExoSeq and Oncoseq BRCA, to genomic testing with Endopredict (a genomic test for those with history of breast cancer) and Niptunegx (a non-invasive genomic test for fetuses).

Endopredict is a genomic test for patients diagnosed with ER+, HER2−, and nodes one to three as both node-negative and node-positive. It runs through a tumor’s biology and pathology to provide a well-rounded view of a patient’s risk of early and late recurrence in the upcoming ten to fifteen years.

NIPTunegx is a non-invasive genetic prenatal test to predict the likelihood of a pregnancy being normal or abnormal through risk score calculation and from a single blood draw.

ExoSeq is a next-generation whole-exome sequencing test that helps identify the genes responsible for any underlying disease. The test focuses on the exon regions in the DNA, all the protein-coding regions, where mutations are usually identified. Another next-generation sequencing test Agiomix has to offer is Oncoseq BRCA, which uses breast cancer panels to focus on detecting mutations in genes BRCA1 and BRCA2, which are essential to identify the potential risk of breast and ovarian cancer in an individual.

“With many projects on hold due to the pandemic, Medlab has created a viable opportunity for Agiomix to showcase its unique position as the only local commercial genetics service provider with international accreditation. In Medlab, Agiomix announced itself to be the only approved lab in the Middle East and Africa to run Endopredict test, a valuable tool for predicating chemotherapy survival, in its own lab” said Dr. Walaa Allam

Agiomix is a DHA-licensed and CAP-accredited genome sequencing and molecular diagnostics laboratory headquartered at the Dubai Science Park. The lab offers a multitude of testing services for genetics, molecular diagnostics, and routine diagnostics applications. Agiomix is equipped with state-of-the-art high throughput testing equipment and has partnered with renowned healthcare providers across the region to make its services available to communities and companies. Learn more by visiting https://agiomix.com/

August 24th, 2021|

Agiomix is selected as the Official Operator for the Egyptian Genome Project

Egypt has announced its plans to establish a map of the Egyptian human genome and enter the world of precision medicine, the Egyptian President Abdel Fattah El Sisi has been briefed on the development of the project by Prime Minister Mustafa Mabdouli and Minister of Higher Education Khaled Abdel Ghaffar.

Egypt Today website reported that “The project could help Egypt enter the era of precision medicine, gene therapy, and future specialized drugs based on genetic combinations, according to a statement from the Egyptian Presidency Spokesperson Bassam Radi”.

Agiomix has been selected by the project as the Official Operator, under its roles Agiomix will provide technical and operational support for the project as per the signed contract with the Egyptian Center for Research and Regenerative Medicine, that will be entrusted to run the project.

Dr. Walaa Allam, Associate Director of Business development at Agiomix commented on the news, “We take great pride in being part of the “Egyptian Genome Project” family, we believe that our expertise with Genomics in the region will enable us to provide the necessary support to this ambitious project”.

Please read the Press Release https://prn.to/2S9oMma

April 28th, 2021|

AGIOMIX RECEIVES THE FIRST ISO 15189 ACCREDITATION FOR NEXT GENERATION SEQUENCING IN THE REGION

 

Agiomix has received the ISO 15189:2012 Accreditation from the Emirates International Accreditation Centre for Next Generation Sequencing clinical assays.

This makes Agiomix the first and only clinical laboratory in the region to have both the CAP and ISO 15189 accreditation for its Next Generation Sequencing (NGS) clinical genetic testing.

Dr. Walaa Allam, Associate Director of Business development at Agiomix commented, “With this additional reputable international accreditation, Agiomix now has the unique capacity to offer its healthcare partners and patients, unparalleled clinical diagnostics services in the area of genetics. We are very pleased and honored by this accreditation and we look forward to more international recognition as our services and family grow”.

Mr. Saman Setoudeh, Director of Quality Assurance at Agiomix Labs described the process the lab went through as being “rigorous and detailed”, he also commended the review process and explained that the ISO accreditation will add the Lab’s strength and ability to lead the area in clinical genetics applications.

Please read the Press Release https://prn.to/2PyTCmS

March 1st, 2021|

Agiomix announces its 100% compliance with the College of American Pathologists (CAP) proficiency testing for hepatitis B virus (HBV)

Agiomix, a regional accredited lab for molecular and genetic testing, is proud to announce that, further to its accreditation in next generation sequencing, it has fulfilled the CAP proficiency testing requirements for molecular diagnostics. In addition, its result for hepatitis B virus (HBV) was 100% compliant with CAP proficiency testing.

Dr. Salah Al Janabi, Managing Director at Agiomix, commented “Agiomix is committed to providing its customers with the most accurate results for their testing. We are continuously participating in CAP proficiency testing to ensure that results provided to our customers are 100% accurate.”

Checkout the Press Release 

March 1st, 2021|

Agiomix announces its 100% compliance with the College of American Pathologists (CAP) proficiency testing for COVID-19 testing

Agiomix, a regional accredited lab for genetic and molecular testing, is proud to announce that, further to its accreditation in next generation sequencing (NGS), it has fulfilled the CAP proficiency testing requirements for molecular diagnostics. In addition, its result for COVID-19 virus was 100% compliant with CAP proficiency testing.

The College of American Pathologists is the world’s largest organization of board-certified pathologists. CAP accreditation ensures test results are meeting the highest industry standards for clinical laboratory testing.

Dr. Salah Al Janabi, Managing Director at Agiomix, commented “Agiomix is committed to providing its customers with the most accurate results for their testing. We are continuously participating in CAP proficiency testing to ensure that results provided to our customers are 100% accurate.”

September 1st, 2020|

Agiomix announces its 100% compliance with the College of American Pathologists (CAP) proficiency testing for COVID-19 testing

Agiomix, a regional accredited lab for genetic and molecular testing, is proud to announce that, further to its accreditation in next generation sequencing (NGS), it has fulfilled the CAP proficiency testing requirements for molecular diagnostics. In addition, its result for COVID-19 virus was 100% compliant with CAP proficiency testing.

The College of American Pathologists is the world’s largest organization of board-certified pathologists. CAP accreditation ensures test results are meeting the highest industry standards for clinical laboratory testing.

Dr. Salah Al Janabi, Managing Director at Agiomix, commented “Agiomix is committed to providing its customers with the most accurate results for their testing. We are continuously participating in CAP proficiency testing to ensure that results provided to our customers are 100% accurate.”

July 16th, 2020|

Agiomix announces its 100% compliance with the College of American Pathologists (CAP) proficiency testing for hepatitis B virus (HBV)

Agiomix, a regional accredited lab for molecular and genetic testing, is proud to announce that, further to its accreditation in next generation sequencing, it has fulfilled the CAP proficiency testing requirements for molecular diagnostics. In addition, its result for hepatitis B virus (HBV) was 100% compliant with CAP proficiency testing.

Dr. Salah Al Janabi, Managing Director at Agiomix, commented “Agiomix is committed to providing its customers with the most accurate results for their testing. We are continuously participating in CAP proficiency testing to ensure that results provided to our customers are 100% accurate.”

Checkout the Press Release 

 

July 8th, 2020|

Agiomix supports return to work directive with COVID-19 testing in the workplace

 17 June, Dubai – Agiomix, the largest regional lab for molecular and genetic testing in the Middle East and Africa launched an offering to have staff tested for COVID-19 in the workplace to reinforce reopening responsibly schemes and help organizations manage the complexity of this undertaking.

As businesses resume activity, and employees return to the workplace, precautionary hygiene measures, social distancing, ongoing testing and isolation remain crucial in containing the spread of the virus. The organization’s specialists can visit sites, set up isolation areas and collect samples from employees, providing results within 48-60 hours. This will assist with identifying and isolating infected individuals, significantly reducing the spread of the virus and at the same time allowing healthcare providers to deliver the required care to the infected people early enough to help recovery.

As part of its drive to support UAE government initiatives against the pandemic, Agiomix has joined forces with Avivo Group, a collaboration aimed at enhancing access of testing to underserved and vulnerable populations working to significantly reduce the number of infections across the country.

The partnership will catalyze the scientific community to improve COVID-19 testing capabilities, advancement, and accessibility, offering residents of the UAE at-home and in the workplace testing services.

Commenting on the partnership, Dr. Salah Al Janabi, Managing Director at Agiomix, said “As businesses begin to reopen, it is imperative to return to work with the necessary precautions. We will continue to align our efforts to support the Dubai Health Authority’s combat efforts against the pandemic. The laboratory has the capacity to conduct thousands of tests per day and aims to test as many people as possible in the UAE in collaboration with the authorities in order to contain the pandemic and reduce number of infections. With Dubai and Sharjah governments’ decision to resume 100% and 30% of their workforce respectively, we are dedicated to making a vital contribution to this new normal and support the country’s safe return to work.”

Dr. Salah Al Janabi, concluded: “As we return to offices, the partnership is key to support the UAE authorities’ directive to reopen the country, adhering to the nation’s ‘We Are All Responsible initiative’. The country’s strategy, with early steps taken to contain the virus and the efforts of the frontline workers has been praised internationally. As restrictions continue to ease, with businesses and public spaces opening up, those vulnerable such as the elderly, pregnant women, people with special needs as well as those with chronic ailments and immune deficiencies, are still ordered to self-quarantine to ensure health and safety of all. The safety and risk mitigation of the UAE’s employees and residents is of utmost importance and we are prepared to help with the transition to the new reality of a physically distant work environment.”

Commenting on the partnership, Dr. Atul Aundhekar, CEO of Avivo Group, said, “Agiomix uses the Reverse Transcriptase Polymerase Chain Reaction (rTPCR) test. This test is the gold standard diagnostic tool for COVID-19. Avivo Group has a home car division and is licensed to send health care workers to residences on call to conduct the test. Many people are scared to venture out, including the elderly, those with children and people of determination for whom driving to a test center could be difficult. Agiomix is our ideal strategic partner in the UAE during this period.”

Checkout the Press Release 

 

July 8th, 2020|
Go to Top